MRTX stock forecast
Our latest prediction for Mirati Therapeutics, Inc.'s stock price was made on the Jan. 10, 2020 when the stock price was at 98.01$.
In the short term (2weeks), MRTX's stock price should underperform the market by -3.77%. During that period the price should oscillate between -10.64% and +11.80%.
In the medium term (3months), MRTX's stock price should underperform the market by -7.81%. During that period the price should oscillate between -38.55% and +30.76%.Get email alerts
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
At the moment the company generates 6M USD in revenues.
On its last earning announcement, the company reported a loss of -4.71$ per share.
The book value per share is 7.61$
Three months stock forecastJan. 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|